KBC Group NV Lowers Stock Holdings in Labcorp Holdings Inc. $LH

KBC Group NV reduced its stake in Labcorp Holdings Inc. (NYSE:LH) by 4.8% during the first quarter, HoldingsChannel.com reports. The firm owned 108,166 shares of the medical research company’s stock after selling 5,475 shares during the quarter. KBC Group NV’s holdings in Labcorp were worth $28,860,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in LH. REAP Financial Group LLC increased its position in Labcorp by 20.4% during the 4th quarter. REAP Financial Group LLC now owns 218 shares of the medical research company’s stock valued at $55,000 after buying an additional 37 shares in the last quarter. V Square Quantitative Management LLC boosted its holdings in Labcorp by 1.7% in the first quarter. V Square Quantitative Management LLC now owns 2,418 shares of the medical research company’s stock worth $645,000 after acquiring an additional 40 shares in the last quarter. Hilltop Holdings Inc. grew its stake in shares of Labcorp by 2.6% in the fourth quarter. Hilltop Holdings Inc. now owns 1,631 shares of the medical research company’s stock worth $409,000 after acquiring an additional 41 shares during the last quarter. Pinnacle Associates Ltd. grew its stake in shares of Labcorp by 3.9% in the fourth quarter. Pinnacle Associates Ltd. now owns 1,126 shares of the medical research company’s stock worth $282,000 after acquiring an additional 42 shares during the last quarter. Finally, Larson Financial Group LLC increased its holdings in shares of Labcorp by 37.5% during the third quarter. Larson Financial Group LLC now owns 154 shares of the medical research company’s stock valued at $44,000 after acquiring an additional 42 shares in the last quarter. Hedge funds and other institutional investors own 95.94% of the company’s stock.

Insider Activity

In other news, EVP Bryan T. Vaughn sold 234 shares of the stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $286.19, for a total value of $66,968.46. Following the transaction, the executive vice president owned 6,746 shares in the company, valued at $1,930,637.74. This represents a 3.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Kathryn W. Kyle sold 92 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $286.19, for a total transaction of $26,329.48. Following the completion of the transaction, the executive vice president directly owned 3,904 shares in the company, valued at approximately $1,117,285.76. The trade was a 2.30% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 6,991 shares of company stock valued at $1,796,696 in the last quarter. 0.84% of the stock is currently owned by insiders.

Labcorp Stock Down 0.8%

Shares of Labcorp stock opened at $279.10 on Wednesday. Labcorp Holdings Inc. has a twelve month low of $244.52 and a twelve month high of $293.72. The company has a quick ratio of 1.54, a current ratio of 1.73 and a debt-to-equity ratio of 0.68. The company’s 50 day moving average is $267.17 and its 200 day moving average is $268.41. The company has a market cap of $22.89 billion, a price-to-earnings ratio of 24.72, a price-to-earnings-growth ratio of 1.87 and a beta of 0.89.

Labcorp (NYSE:LH) last posted its earnings results on Thursday, April 30th. The medical research company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $4.09 by $0.16. The business had revenue of $3.54 billion during the quarter, compared to the consensus estimate of $3.51 billion. Labcorp had a net margin of 6.66% and a return on equity of 16.29%. The firm’s revenue was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.84 EPS. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. Research analysts anticipate that Labcorp Holdings Inc. will post 18 EPS for the current year.

Labcorp Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 28th will be paid a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date is Friday, August 28th. Labcorp’s payout ratio is currently 25.51%.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on LH. Wall Street Zen raised Labcorp from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Weiss Ratings restated a “buy (b-)” rating on shares of Labcorp in a research note on Friday, May 8th. Robert W. Baird lifted their target price on shares of Labcorp from $335.00 to $338.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Evercore reiterated an “outperform” rating and issued a $300.00 target price on shares of Labcorp in a research note on Wednesday, April 8th. Finally, Bank of America increased their price target on shares of Labcorp from $300.00 to $320.00 and gave the company a “buy” rating in a report on Monday, July 13th. Nine equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $314.40.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.